X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 1
globenewswire.comX4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 27
zacks.comBears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Nowzacks.comMay 20
zacks.comX4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Knowzacks.comMay 18
zacks.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 6